Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.1 Worldwide, more than 220,000 people are living with multiple myeloma and approximately 100,000 new cases are diagnosed annually.2
Onyx is conducting multiple trials evaluating carfilzomib as a monotherapy in relapsed and/or refractory multiple myeloma patients and in combination with other anticancer agents and chemotherapies.
For a more comprehensive list of carfilzomib clinical trials, please visit www.clinicaltrials.gov.
Currently enrolling
Study Design: Randomized, open-label, multicenter
Patients: Patients whose multiple myeloma has relapsed after at least one, but not more than three prior therapeutic regimens
Purpose: To compare effectiveness of carfilzomib in combination with dexamethasone when compared to bortezomib in combination with dexamethasone by assessing the difference in progression-free survival (PFS).
Locations: Multiple sites worldwide
Enrollment Complete
Study Design: Randomized, open-label, multicenter
Patients: Patients with relapsed and refractory multiple myeloma who received at least three prior treatments including currently available classes of anti-myeloma agents, were refractory to most recent therapy, but who were responsive to at least one therapy, and who received prior treatment with all available anti-myeloma agents
Purpose: To compare effectiveness of carfilzomib when compared to best supportive care (low dose corticosteroid +/ low dose alkylating agents) by assessing the difference in overall survival (OS)
Locations: Multiple sites throughout Europe
Enrollment Complete
Study Design: Randomized, open-label, multicenter
Patients: Patients with relapsed multiple myeloma who received one to three prior treatments
Purpose: To determine the effectiveness of carfilzomib plus lenalidomide and low-dose dexamethasone when compared to lenalidomide and low-dose dexamethasone alone by assessing the difference in progression-free survival (PFS), as well as to measure overall response rate, safety and efficacy
Location: Multiple centers throughout the U.S., Canada, Europe and Israel
[i] American Cancer Society, Cancer Facts & Figures 2012
[ii] International Agency for Research on Cancer, GLOBOCAN 2010
